{"id":"NCT02081391","sponsor":"Gr√ºnenthal GmbH","briefTitle":"A Study to Look at Tapentadol Oral Solution in Children and Adolescents in Pain","officialTitle":"An Evaluation of the Efficacy and Safety of Tapentadol Oral Solution in the Treatment of Post-operative Acute Pain Requiring Opioid Treatment in Pediatric Subjects Aged From Birth to Less Than 18 Years Old","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-02-19","primaryCompletion":"2019-03-03","completion":"2019-03-14","firstPosted":"2014-03-07","resultsPosted":"2020-01-18","lastUpdate":"2020-01-18"},"enrollment":216,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Acute Pain"],"interventions":[{"type":"DRUG","name":"Tapentadol oral solution 4 mg/mL","otherNames":[]},{"type":"DRUG","name":"Tapentadol oral solution 20 mg/mL","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Tapentadol immediate-release (IR)","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of the study was to evaluate the efficacy of tapentadol oral solution, based on the total amount of supplemental opioid analgesic used over 12 hours or 24 hours after initiation of investigational medicinal product (IMP) in children and adolescents who had undergone surgery that would produce moderate to severe pain during opioid treatment.","primaryOutcome":{"measure":"For the US FDA: The Total Amount of Supplemental Opioid Analgesic Medication Used Within the First 12 Hours After First Intake of Investigational Medicinal Product (IMP) [Tapentadol Oral Solution or Placebo]","timeFrame":"Up to 12 hours","effectByArm":[{"arm":"Tapentadol (From 2 to <18 Years)","deltaMin":0.08,"sd":0.01},{"arm":"Placebo (From 2 to <18 Years)","deltaMin":0.13,"sd":0.02}],"pValues":[{"comp":"OG000 vs OG001","p":"0.0404"}]},"eligibility":{"minAge":"1 Day","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":43,"countries":["United States","Bulgaria","Croatia","Czechia","France","Germany","Hungary","Poland","Spain","United Kingdom"]},"refs":{"pmids":["6726515"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":2,"n":160},"commonTop":["Vomiting","Nausea","Constipation","Pyrexia","Somnolence"]}}